Kyverna Therapeutics Presents Updated Results From Its Phase 1 Trial Of CD-19 Directed CAR T-Cell Therapy In Progressive Multiple Sclerosis At MS Toronto 2026

Loading news article.

Kyverna Therapeutics Presents Updated Results From Its Phase 1 Trial Of CD-19 Directed CAR T-Cell Therapy In Progressive Multiple Sclerosis At MS Toronto 2026 | WAPE

Kyverna Therapeutics Presents Updated Results From Its Phase 1 Trial Of CD-19 Directed CAR T-Cell Therapy In Progressive Multiple Sclerosis At MS Toronto 2026

Article summary

Related companies

Analyzed by WAPE AI.

Comments —